Develops mRNA-based therapeutics and vaccines that instruct the body to produce proteins targeting cancer, infectious diseases, and rare disorders. By leveraging proprietary mRNA design, delivery platforms, and self-amplifying technologies, the company creates personalized cancer treatments, prophylactic vaccines, and therapies for hard-to-treat conditions, addressing significant gaps in current medical options.
Funding
$37M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current medical options often fall short in addressing complex diseases like cancer, infectious diseases, and rare disorders, leaving significant unmet needs in treatment and prevention. Traditional approaches may lack the precision, adaptability, and scalability required to effectively target these conditions.
Solution
RNAimmune develops mRNA-based therapeutics and vaccines that instruct the body to produce its own proteins to combat a wide range of diseases. The company leverages its expertise in mRNA design, proprietary delivery methods including Lipid Nanoparticle (LNP) and Polypeptide Lipid Nanoparticle (PLNP) based carriers, and self-amplifying mRNA technology to create innovative medical solutions. These technologies enable the development of personalized cancer treatments, prophylactic vaccines against infectious diseases, and therapies for difficult-to-treat rare diseases. RNAimmune's approach aims to optimize immune response through synthetic biology and AI-aided platforms, enhancing intracellular expression and targeted delivery for stronger and longer potency.
Target Audience
The primary target audience includes individuals and healthcare providers seeking innovative treatments and preventative measures for cancer, infectious diseases, and rare disorders.
Features
- AI-aided mRNA design platform to optimize immune system response
- Lipid Nanoparticle (LNP) and Polypeptide Lipid Nanoparticle (PLNP) based carriers for enhanced mRNA delivery
- Self-amplifying mRNA technology for stronger and longer potency
- Antigen engineering to optimize vaccines at the protein level
- Development of individualized neoantigen-based therapeutic cancer vaccines
- Focus on multi-target prophylactic vaccines and cancer vaccines expressing tumor-targeted epitopes